Home › Research › Treatments
The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome
Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, Heller JH, Richardson S et al.. American journal of medical genetics. Part A, 2009-08-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
The objective of our study was to assess the efficacy and safety of donepezil in young adults with Down syndrome (DS) but no evidence of Alzheimer disease (AD). A 12-week, randomized, double-blind, placebo-controlled study with a 12-week, open-label extension was conducted. The intervention consisted of donepezil (5-10 mg/day) in young adults (aged 18-35 years) with DS, but no AD. The primary measure was the Severe Impairment Battery (SIB) test and secondary measures were the Vineland Adaptive Behavior Scales (VABS), the Rivermead Behavioral Memory Test for Children, and the Clinical Evaluation of Language Fundamentals, Third Edition. At baseline, 123 subjects were randomly assigned treatment with donepezil or placebo. During the double-blind phase, SIB scores improved significantly from baseline in both groups, with no significant between-group differences. During the open-label phase, SIB scores in the original donepezil group remained stable; the original placebo group showed an improvement similar to that seen in the double-blind phase. VABS scores improved for donepezil, but not placebo, during the double-blind phase (observed cases, P = 0.03; last observation carried forward, P = 0.07). Post hoc responder analyses were significant for donepezil using three of five response definitions (P < or = 0.045). Adverse event rates were comparable to AD studies. In this first large-scale, multicenter trial of a pharmacological agent for DS, donepezil appears safe. Efficacy interpretation was limited for the primary measure due to apparent learning/practice and ceiling effects. Outcomes in post hoc analyses suggested efficacy in some, but not all subjects, consistent with phenotypic variability of DS. Additional studies are required to confirm potential benefits of donepezil in this population.
What this study adds
Evidence grade: High
This is a trial of 123 participants. In young adults with Down syndrome but no Alzheimer's disease, donepezil did not significantly differ from placebo on the main cognitive measure. Reported effect size: or = 0.045.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kishnani, P. S., Sommer, B. R., Handen, B. L., Seltzer, B., Capone, G. T., Spiridigliozzi, G. A., et al. (2009). The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. American journal of medical genetics. Part A. https://doi.org/10.1002/ajmg.a.32953
Vancouver
Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, et al. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. American journal of medical genetics. Part A. 2009. doi:10.1002/ajmg.a.32953. PMID: 19606472.
BibTeX
@article{kishnani2009-19606472,
author = {Kishnani, P. S. and Sommer, B. R. and Handen, B. L. and Seltzer, B. and Capone, G. T. and Spiridigliozzi, G. A. and Heller, J. H. and Richardson, S. and others},
title = {{The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome}},
journal = {American journal of medical genetics. Part A},
year = {2009},
doi = {10.1002/ajmg.a.32953},
pmid = {19606472},
url = {https://doi.org/10.1002/ajmg.a.32953}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- During the double-blind phase, SIB scores improved significantly from baseline in both groups, with no significant between-group differences.
- Post hoc responder analyses were significant for donepezil using three of five response definitions (P < or = 0.045).
Why it matters
In young adults with Down syndrome but no Alzheimer's disease, donepezil did not significantly differ from placebo on the main cognitive measure. This study does not show that donepezil prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designopen-label trial
- Participants123
- Effect sizeor = 0.045
- Evidence strengthHigh
How this study scored 67/100
Published in a peer-reviewed journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American journal of medical genetics. Part A) |
| Journal's citation record | 2 / 4 | American Journal of Medical Genetics Part A: journal h-index 161 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 123 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 58 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.1 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 3 / 6 | Cited 5.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Thomas D. McRae: h-index 25 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19606472) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.